MN-001, a potential treatment for idiopathic pulmonary fibrosis (IPF), will soon have patent protections in China. MediciNova, the…
Articles by Marisa Wexler, MS
Esbriet (pirfenidone) shows similar benefits for people with idiopathic pulmonary fibrosis (IPF) in real-world settings as it does in…
Men who are active smokers and experience faster respiratory decline when diagnosed with idiopathic pulmonary fibrosis (IPF) are at greater…
Low body mass index (BMI) is a risk factor for nausea and diarrhea as side effects of Ofev…
Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or…
When idiopathic pulmonary fibrosis (IPF) runs in families, it tends to begin earlier in life and be more severe,…
A less toxic precursor formulation of the chemotherapeutic agent paclitaxel can reduce lung…
The use of oxygen at rest is associated with a greater likelihood of death or lung transplant in people with…
The U.S. Food and Drug Administration has granted breakthrough therapy designation to PRM-151, a compound being investigated for the…